Page 172 - 2018_12-Haematologica-web

M.A. Dimopoulos et al. Haematologica. 2016;101(4):396-406.
23. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and mini- mal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328- e346.
24. Avet-Loiseau H, Casneuf T, Chiu C, et al. Evaluation of minimal residual disease (MRD) in relapsed/refractory multiple myeloma (RRMM) patients treated with daratumumab in combination with lenalidomide plus dexamethasone or borte- zomib plus dexamethasone. Blood. 2016; 128(22):246.
25. Dimopoulos A, Stewart AK, Rajkumar SV, et al. Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: secondary analysis from an
interim analysis of the phase III study ASPIRE (NCT01080391). J Clin Oncol. 2015;33(15_suppl):8525.
26. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142- 152.
27. Ludwig H, Dimopoulos MA, Masszi T, et al. Carfilzomib, lenalidomide, and dexam- ethasone (KRd) vs lenalidomide and dex- amethasone (Rd) in patients with relapsed multiple myeloma (RMM) and early pro- gression during prior therapy: Secondary analysis from the phase 3 study ASPIRE (NCT01080391). J Clin Oncol. 2016;34(15_suppl):8045.
28. Lonial S, Richardson PG, Mateos MV, et al. ELOQUENT-2 update: Phase III study of elotuzumab plus lenalidomide/dexametha- sone (ELd) vs Ld in relapsed/refractory mul-
tiple myeloma (RRMM)-identifying responders by subset analysis. J Clin Oncol. 2016;34(15_suppl):8037.
29. Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refrac- tory multiple myeloma. N Engl J Med. 2015;373(7):621-631.
30. Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexametha- sone for multiple myeloma. N Engl J Med. 2016;374(17):1621-1634.
31. Mateos MV, Estell J, Barreto W, et al. Efficacy of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory myeloma based on prior lines of therapy: updated analysis of CASTOR. Presented at the 58th Annual Meeting & Exposition of the American Society of Hematology (ASH); December 3-6, 2016; San Diego, CA. Abstract 1150.
2096
haematologica | 2018; 103(12)